First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population.

IF 3 4区 医学 Q2 ONCOLOGY
Maria Jakobsson, Fredrik Nilsson, Angela Strambi, Johannes Arpegård, Johan Dalén
{"title":"First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population.","authors":"Maria Jakobsson, Fredrik Nilsson, Angela Strambi, Johannes Arpegård, Johan Dalén","doi":"10.1080/14796694.2024.2401309","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Assess first-line sunitinib dosing for treatment of metastatic renal cell carcinoma in Swedish clinical practice (2006-2019).<b>Materials & methods:</b> Retrospective analysis of three sunitinib dosing regimens: 2-weeks on, 1-week off (2:1 Start); standard 4-weeks on, 2-weeks off (4:2) and 4:2 start with switch to 2:1 (2:1 Switch).<b>Results:</b> Time-to-treatment discontinuation (95% CI) differed significantly (<i>p</i> < 0.001): 6.2 (5.6-7.2), 13.9 (8.1-20.6) and 4.6 (4.3-5.6) months for 2:1 Start (<i>n</i> = 320), 2:1 Switch (<i>n</i> = 71) and 4:2 (<i>n</i> = 704), respectively. Overall survival (95% CI) differed significantly (<i>p</i> < 0.001): 21.8 (18.1-26.1), 32.2 (25.1-48.3) and 13.5 (12.3-15.8) months for 2:1 Start (<i>n</i> = 320), 2:1 Switch (<i>n</i> = 71) and 4:2 (<i>n</i> = 704), respectively.<b>Conclusion:</b> Alternative dosing does not compromise clinical efficacy and may provide advantages in terms of improved treatment outcomes. However, due to the changing treatment patterns during this long-term study, and the absence of patient risk category data, caution is required when interpreting the main outcomes.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2401309","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Assess first-line sunitinib dosing for treatment of metastatic renal cell carcinoma in Swedish clinical practice (2006-2019).Materials & methods: Retrospective analysis of three sunitinib dosing regimens: 2-weeks on, 1-week off (2:1 Start); standard 4-weeks on, 2-weeks off (4:2) and 4:2 start with switch to 2:1 (2:1 Switch).Results: Time-to-treatment discontinuation (95% CI) differed significantly (p < 0.001): 6.2 (5.6-7.2), 13.9 (8.1-20.6) and 4.6 (4.3-5.6) months for 2:1 Start (n = 320), 2:1 Switch (n = 71) and 4:2 (n = 704), respectively. Overall survival (95% CI) differed significantly (p < 0.001): 21.8 (18.1-26.1), 32.2 (25.1-48.3) and 13.5 (12.3-15.8) months for 2:1 Start (n = 320), 2:1 Switch (n = 71) and 4:2 (n = 704), respectively.Conclusion: Alternative dosing does not compromise clinical efficacy and may provide advantages in terms of improved treatment outcomes. However, due to the changing treatment patterns during this long-term study, and the absence of patient risk category data, caution is required when interpreting the main outcomes.

mRCC患者的一线舒尼替尼治疗调整:瑞典全国人口分析。
目的:评估瑞典临床实践中治疗转移性肾细胞癌的一线舒尼替尼剂量(2006-2019年):对三种舒尼替尼用药方案进行回顾性分析:2周用药,1周停药(2:1 Start);标准4周用药,2周停药(4:2)和4:2 start with switch to 2:1(2:1 Switch):停止治疗的时间(95% CI)差异显著(p n = 320),分别为 2:1 Switch(n = 71)和 4:2(n = 704)。总生存期(95% CI)差异显著(p n = 320),分别为2:1 Switch(n = 71)和4:2(n = 704):替代剂量不会影响临床疗效,并可能在改善治疗结果方面带来优势。然而,由于在这项长期研究中治疗模式不断变化,而且缺乏患者风险类别数据,因此在解释主要结果时需要谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信